Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 1;108(6):1691-1696.
doi: 10.3324/haematol.2022.282162.

Retrospective analysis of a cohort of 41 de novo B-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a FILO study)

Caroline Algrin  1 , Louis Pérol  2 , Elise Chapiro  3 , Lucile Baseggio  4 , Karim Maloum  5 , Catherine Settegrana  6 , Jean-François Lesesve  7 , Justine Siavellis  8 , Alain Delmer  9 , Anne-Sophie Michallet  10 , Emmanuelle Ferrant  11 , Pierre Feugier  12 , Cécile Tomowiak  13 , Annie Brion  14 , David Ghez  15 , Luc-Matthieu Fornecker  16 , Sarah Ivanoff  8 , Stéphanie Struski  17 , Laurent Sutton  18 , Isabelle Radford-Weiss  19 , Virginie Eclache  20 , Christine Lefebvre  21 , Véronique Leblond  2 , Florence Nguyen-Khac  3 , Damien Roos-Weil  22
Affiliations

Retrospective analysis of a cohort of 41 de novo B-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a FILO study)

Caroline Algrin et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Outcomes of B-cell prolymphocytic leukemia patients. Kaplan-Meier estimates of (A) overall survival (OS) (n=41) and (B) progression-free survival (PFS) (n=34) in the whole cohort. Kaplan-Meier estimates of (C) OS and (D) PFS according to the presence of del17p (no del17p, red; del17p, blue). Kaplan-Meier estimates of (E) OS and (F) PFS according to the treatment received (blue: Bruton tyrosine kinase inhibitor [BTKi]; red: chemotherapy or chemoimmunotherapy [CT/CIT]) among del17p patients.
See this image and copyright information in PMC

References

    1. Swerdlow SH, Campo E, Pileri SA, et al. . The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-2390. - PMC - PubMed
    1. Dearden C. Management of prolymphocytic leukemia. Hematol Am Soc Hematol Educ Program. 2015;2015:361-367. - PubMed
    1. Cross M, Dearden C. B and T cell prolymphocytic leukaemia. Best Pract Res Clin Haematol. 2019;32(3):217-228. - PubMed
    1. Hercher C, Robain M, Davi F, et al. . A multicentric study of 41 cases of B-prolymphocytic leukemia: two evolutive forms. Leuk Lymphoma. 2001;42(5):981-987. - PubMed
    1. Chapiro E, Pramil E, Diop M, et al. . Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53. Blood. 2019;134(21):1821-1831. - PubMed

MeSH terms